Date of Presentation
5-2-2024 12:00 AM
College
Rowan-Virtua School of Osteopathic Medicine
Poster Abstract
Parkinson’s Disease (PD) is a prevalent and devastating neurodegenerative disorder that causes progressively worsening motor symptoms affecting locomotor and oropharyngeal function. There is limited research in animal models on swallowing dysfunction in PD. To examine how neurodegeneration in PD produces progressive impairment in the oropharyngeal and locomotor processes, rotenone, a type II mitochondrial inhibitor, was injected into Lewis rat models to reproduce a parkinsonian phenotype. We hypothesized that the animal models injected with the rotenone will exhibit both oropharyngeal dysfunction and locomotor deficiency with an increased deficit that correlates with prolonged treatment. We utilized 18 rats receiving either 2.75 mg/kg of rotenone or vehicle intraperitoneal injections. Animals received daily injections for 17 or 8 days. At the end of the injections in each group brains were perfused and immunostained for striatal tyrosine hydroxylase (TH). Videofluoroscopic recording was taken of these rats and average chew cycle length and total chewing time data were collected from days 0, 1, 4, 7 and 16 of those recordings. From these recordings the number of chewing cycles prior to a swallow were counted, total time chewing was measured, and average duration of a chewing cycle was calculated. The number of rears by a rat in a glass cylinder over 4 minutes was counted on the same days to assess locomotor behavior. Total chewing time and average chew cycle duration increased in rotenone treated rats from day 0 to day 4, but the difference disappeared from day 7 onwards. However, rearing behavior was consistently reduced in rotenone treated rats for all 16 days. Tyrosine hydroxylase staining intensity in the striatum decreased consistently over the course of the injections. These results suggest that rotenone treated rats have temporary/short term deficiency in chewing function. The restoration of function after day 4 may indicate a learned behavior to compensate for this dysfunction in chewing, or point to a different neurological impairment than that seen in locomotor behavior. Further research needs to be undertaken to address this phenomenon.
Keywords
Parkinson's, Parkinson Disease, oropharyngeal behavior, Deglutition Disorders, Dysphagia, locomotor behavior, oropharyngeal dysfunction, locomotor dysfunction, Locomotor Activity
Disciplines
Disease Modeling | Kinesiology | Medicine and Health Sciences | Nervous System Diseases | Neurology | Neuroscience and Neurobiology | Pathological Conditions, Signs and Symptoms | Stomatognathic System
Document Type
Poster
Included in
Disease Modeling Commons, Kinesiology Commons, Nervous System Diseases Commons, Neurology Commons, Neuroscience and Neurobiology Commons, Pathological Conditions, Signs and Symptoms Commons, Stomatognathic System Commons
Effect of Dosage on Severity of Dysphagia in a Toxicological Rat Model of Parkinson's Disease
Parkinson’s Disease (PD) is a prevalent and devastating neurodegenerative disorder that causes progressively worsening motor symptoms affecting locomotor and oropharyngeal function. There is limited research in animal models on swallowing dysfunction in PD. To examine how neurodegeneration in PD produces progressive impairment in the oropharyngeal and locomotor processes, rotenone, a type II mitochondrial inhibitor, was injected into Lewis rat models to reproduce a parkinsonian phenotype. We hypothesized that the animal models injected with the rotenone will exhibit both oropharyngeal dysfunction and locomotor deficiency with an increased deficit that correlates with prolonged treatment. We utilized 18 rats receiving either 2.75 mg/kg of rotenone or vehicle intraperitoneal injections. Animals received daily injections for 17 or 8 days. At the end of the injections in each group brains were perfused and immunostained for striatal tyrosine hydroxylase (TH). Videofluoroscopic recording was taken of these rats and average chew cycle length and total chewing time data were collected from days 0, 1, 4, 7 and 16 of those recordings. From these recordings the number of chewing cycles prior to a swallow were counted, total time chewing was measured, and average duration of a chewing cycle was calculated. The number of rears by a rat in a glass cylinder over 4 minutes was counted on the same days to assess locomotor behavior. Total chewing time and average chew cycle duration increased in rotenone treated rats from day 0 to day 4, but the difference disappeared from day 7 onwards. However, rearing behavior was consistently reduced in rotenone treated rats for all 16 days. Tyrosine hydroxylase staining intensity in the striatum decreased consistently over the course of the injections. These results suggest that rotenone treated rats have temporary/short term deficiency in chewing function. The restoration of function after day 4 may indicate a learned behavior to compensate for this dysfunction in chewing, or point to a different neurological impairment than that seen in locomotor behavior. Further research needs to be undertaken to address this phenomenon.